Scleral lenses for severe chronic GvHD-related keratoconjunctivitis sicca: a retrospective study by the SFGM-TC.
Fiche publication
Date publication
juin 2017
Journal
Bone marrow transplantation
Auteurs
Membres identifiés du Cancéropôle Est :
Pr RUBIO Marie Thérèse
Tous les auteurs :
Magro L, Gauthier J, Richet M, Robin M, Nguyen S, Suarez F, Dalle JH, Fagot T, Huynh A, Rubio MT, Oumadely R, Vigouroux S, Milpied N, Delcampe A, Yakoub-Agha I
Lien Pubmed
Résumé
Chronic GvHD-related keratoconjunctivitis sicca (cGvHD-related KCS) can significantly alter the quality of life of patients after allogeneic hematopoietic stem cell transplantation. The aim of this work was to assess the efficacy and tolerability of scleral lenses to treat severe cGvHD-related KCS. In this retrospective, multicenter study, we included 60 consecutive patients diagnosed with cGvHD-related KCS and fitted with scleral lenses. Patients were evaluated at baseline and at 2 months with the following tests: the Ocular Surface Disease Index (OSDI) to assess quality of life, the Oxford score to grade corneal damage and the logarithm of minimal angle of resolution (Log MAR) scale to determine visual acuity. We observed improvement in quality of life in 58 patients (97%). All parameters improved at 2 months. We observed significant differences at 2 months compared with baseline for the mean OSDI (86 versus 30, respectively, P<0.001), the mean Oxford score (3.2 versus 1.3, respectively, P<0.001) as well as visual acuity (Log MAR of 0.33 versus 0.10, respectively, P<0.001). Treatment with scleral lenses was discontinued in only 5 patients (8%) with a median follow-up of 20.5 months (range: 2-125 months). Scleral lenses were very efficient and well tolerated in patients with severe cGvHD-related KCS.
Mots clés
Adolescent, Adult, Aged, Allografts, Child, Chronic Disease, Female, Graft vs Host Disease, pathology, Hematopoietic Stem Cell Transplantation, Humans, Keratoconjunctivitis Sicca, etiology, Lens Capsule, Crystalline, pathology, Male, Middle Aged, Quality of Life, Retrospective Studies, Severity of Illness Index
Référence
Bone Marrow Transplant.. 2017 Jun;52(6):878-882